Abstract: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable tablet dosage forms. Also provided is packaging that discourages the use of rapidly bioavailable acute pain medications for off-label chronic pain treatment, and that allows such dosage forms to be manufactured and stored for prolonged periods of time.

Abstract: The present invention relates generally to methods for identifying drug side effects by detecting perturbations in organ-specific molecular blood fingerprints. The invention further relates to methods for identifying drug-specific organ-specific molecular blood fingerprints. As such, the present invention provides compositions comprising organ-specific proteins, detection reagents for detecting such proteins, and panels and arrays for determining organ-specific molecular blood fingerprints.

Abstract: Crystalline polymorphs of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide which are useful as pharmaceutical agents are disclosed. Methods of production and isolation of these polymorphs and pharmaceutical compositions which include these polymorphs and pharmaceutical methods of treatment are also disclosed. The crystalline polymorphs of the present invention are useful as they act directly on the pituitary gland cells to release growth hormone.

Abstract: Immunosorbents, kits and compositions for diagnosing a central nervous system disorder, particularly paroxysmal cerebral discharges and epilepsy, comprising measuring the concentration of GluR1 or fragment thereof and/or GluR1 antibodies in a biological sample from a human subject. The method is particularly useful for identifying individuals that are at risk for brain related seizures and epilepsy, for distinguishing epilepsy from pseudo-epilepsy and epilepsy-like disorders, for following up after anticonvulsive treatment, and for the adjustment of adequate therapy and doses.

Abstract: Disclosed are compositions and methods for treating ischemia and molecules related to hibernation states. FPA molecules having the sequence set forth in SEQ ID NO: 2 can be used for as anti-infarction agents.

Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis.

Abstract: It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies.

Abstract: The invention provides polypeptides comprising inhibitor of apoptosis protein (IAP) family members, such as BmIAP initially derived from Bombyx mori BmN cells, and nucleic acids encoding them, and methods for making and using these compositions, including their use for inhibiting apoptosis.

Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.

Abstract: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms.

Abstract: The present invention relates to excipients for the production of rapidly bioavailable solid oral dosage forms of diclofenac. In particular, the invention relates to the use of excipients that promote the bioavailability of such formulations, including alkaline buffering agents, gas forming excipients, hygroscopic excipients, water soluble diluents, wetting agents, and particular pharmaceutically acceptable salts.

Abstract: A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.

Abstract: A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.

Abstract: A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.

Abstract: The present invention provides methods of producing a clone non-human mammalian nuclear transfer (NT) embryo and methods for producing a cloned non-human mammal. Embodiments of the methods include introducing doner genetic material into a metaphase I oocyte; introducing donor genetic material into a non-enucleated oocyte; introducing donor genetic material obtained from a donor cell that is a metaphase into an oocyte; introducing donor genetic material into an oocyte, and naturally activating the oocyte or the NT embryo; and introducing donor genetic material obtained from a donor cell that is at late G1 phase into anoocyte.

Abstract: Mineral additives for preparing tablet compositions that comprise Vitamin E and optionally saw palmetto. The compositions are preferably formulated with a zinc compound and a selenium compound.

Abstract: Methods are disclosed for identifying oligosaccharides found on proteins and identifying those that are modified in disease states.

Abstract: A computational circuit for generating a predicted address value includes an instruction field that contains an instruction value. A value immediate field is associated with the instruction field and includes a offset value and a first subset of lower-order bits. An effective address cache stores a plurality of higher-order bits of a plurality of recently-accessed memory addresses and reads out a value corresponding to a second subset of higher-order bits of a memory address that corresponds to the first subset of lower-order bits. A circuit concatenates the second subset, the first subset and the offset value, thereby generating the predicted address value.

Abstract: An apparatus for executing an instruction in a computational pipeline includes a first instruction memory. The first instruction memory includes a first plurality of instruction fields, each of which is capable of holding an instruction therein. Each of a first plurality of value fields is uniquely associated with a corresponding instruction field from the first plurality of instruction fields. Each value field is capable of holding a data value therein that is likely to be required in executing an instruction held in the instruction field.

Abstract: A storage and location tracking system for objects, such as keys, with at least one storage container having a selectively accessible interior with a plurality of object holders therein, and each of the holders can store one or more objects. An access control tracks the storage and removal of objects from the plurality of holders and randomly assigns a holder for storage of objects such that an object is not consecutively stored at the same holder within the container.